Assertio Therapeutics (NASDAQ: ASRT) reported Q4 EPS of ($1.06), $0.99 worse than the analyst estimate of ($0.07). Revenue for the quarter came in at $13.54 million versus the consensus estimate of $28.36 million.

For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.